Bioimaging of nanoparticles: the crucial role of discriminating nanoparticles from free probes.

ABSTRACT

The biological fate of nanocarriers has yet to be fully explored, mainly because of the lack of functional tools like probes to identify integral nanocarriers in the body. Understanding their in vivo fate remains as the bottleneck to the development of nanomedicines. Bioimaging results based on conventional fluorescent or radioactive probes should be judged critically because images merely reflect bulk signals of an admixture of the nanoparticles and free probes. It is crucial to discriminate between nanocarrier-bound and free signals. This review analyzes the state-of-the-art of bioimaging of nanoparticles in vivo and highlights directions for future endeavours.